Currently, Relay Therapeutics Inc [RLAY] is trading at $6.59, up 3.45%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RLAY shares have gain 10.76% over the last week, with a monthly amount drifted -20.60%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Relay Therapeutics Inc [NASDAQ: RLAY] stock has seen the most recent analyst activity on April 20, 2023, when Jefferies upgraded its rating to a Hold but kept the price target unchanged to $12.50 for it. Previously, Raymond James upgraded its rating to Strong Buy on April 19, 2023, and kept the price target unchanged to $29. On April 13, 2023, Raymond James initiated with a Outperform rating and assigned a price target of $29 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $33 on February 03, 2023. Barclays initiated its recommendation with a Equal Weight and recommended $23 as its price target on September 30, 2022. Stifel started tracking with a Buy rating for this stock on September 02, 2022, and assigned it a price target of $40. In a note dated June 06, 2022, Jefferies initiated an Underperform rating and provided a target price of $13 on this stock.
This stock has fluctuated between a low of $5.70 and a high of $13.32 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $22.83 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $6.59 at the most recent close of the market. An investor can expect a potential return of 246.43% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
Trailing Twelve Months sales for Relay Therapeutics Inc [NASDAQ:RLAY] were 25.55M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -14.6%, Pretax Profit Margin comes in at -13.39%, and Net Profit Margin reading is -13.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.42 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.37 points at the first support level, and at 6.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.79, and for the 2nd resistance point, it is at 6.99.
Relay Therapeutics Inc [RLAY] reported earnings per share of -$0.67 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.73/share, meaning a difference of $0.06 and a surprise factor of 8.20%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.54 per share as compared to estimates of -$0.83 per share, a difference of $0.29 representing a surprise of 34.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Relay Therapeutics Inc [NASDAQ:RLAY] is 25.44. Further, the Quick Ratio stands at 25.44, while the Cash Ratio is 4.75. Considering the valuation of this stock, the price to sales ratio is 34.13, the price to book ratio is 1.12.
Transactions by insiders
Recent insider trading involved Bergstrom Donald A, President, R&D, that happened on Apr 29 ’24 when 2686.0 shares were sold. Chief Financial Officer, Catinazzo Thomas completed a deal on Apr 29 ’24 to sell 1695.0 shares. Meanwhile, Chief Legal Officer Adams Brian sold 1623.0 shares on Apr 29 ’24.
